Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

Publisher： Karger

E-ISSN： 1421-9662|120|2|104-107

ISSN： 0001-5792

Source： Acta Haematologica, Vol.120, Iss.2, 2008-10, pp. : 104-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes

By  

Oncology Research and Treatment, Vol. 23, Iss. 1, 2000-03 ,pp. : 12-16

Karger

Access to resources Recommend Favorite

Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

By  

Oncology Research and Treatment, Vol. 28, Iss. 4, 2005-10 ,pp. : 216-221

Karger

Access to resources Recommend Favorite

rHuEPO Dose Inversely Correlated with the Number of Circulating CD34+ Cells in Maintenance Hemodialysis Patients

By  

Nephron Clin Pract, Vol. 108, Iss. 1, 2007-12 ,pp. : c41-c46

Karger

Access to resources Recommend Favorite

Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin (rHuEpo): A Prospective, Open Label, Randomized Trial by the Hellenic Cooperative Oncology Group

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 102-110

Karger

Access to resources Recommend Favorite

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

By Villegas A.   Arrizabalaga B.   Fernáández-Lago C.   Castro M.   Mayans J.R.   Gonzáález-Porras J.R.   Duarte R.F.   Remacha A.F.   Luñño E.   Gasquet J.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 951-960

Informa Healthcare

Access to resources Recommend Favorite